Insulet reported $943M in Loan Capital for its fiscal quarter ending in September of 2026.





Loan Capital Change Date
Abbott USD 29.45B 152M Sep/2026
Align Technology USD 0 0 Dec/2024
AtriCure USD 61M 0 Sep/2026
Baxter International USD 8.62B 6M Jun/2026
Becton, Dickinson and Co. USD 13.42B 89M Sep/2026
Boston Scientific USD 10.79B 73M Jun/2026
Cardinal Health USD 6.93B 75M Sep/2026
Cooper Companies USD 1.92B 54.8M Jun/2026
Dexcom USD 1.3B 200K Jun/2026
Edwards Lifesciences USD 598.8M 100K Sep/2026
Eli Lilly USD 46.99B 872M Sep/2026
Globus Medical USD 326K 54K Sep/2026
ICU Medical USD 1.13B 79.35M Sep/2026
Inogen USD 0 0 Jun/2022
Insulet USD 943M 13.5M Sep/2026
Integra LifeSciences USD 1.83B 2.12M Sep/2026
J&J USD 35.8B 1.55B Sep/2026
Medtronic USD 25.62B 502M Jun/2026
Merit Medical Systems USD 737.4M 1.15M Sep/2026
Roche Holding CHF 25.22B 2.21B Jun/2026
Solventum Corp USD 4.56B 12M Sep/2026
Stryker USD 14.18B 16M Sep/2026
Tandem Diabetes Care USD 603.39M 811K Sep/2026
Teleflex USD 1.53B 1.19B Sep/2026
West Pharmaceutical Services USD 202.9M 0 Sep/2026
Zimmer Biomet Holdings USD 6.22B 61M Sep/2026